《2023年国际多学科专家共识:代谢相关脂肪性肝病和慢性肾脏病风险》摘译  

An excerpt of an international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease(2023)

作　　者：孙旦芹 沈嘉琪 郑明华[2] SUN Danqin;SHEN Jiaqi;ZHENG Minghua(Department of Nephrology,Jiangnan University Medical Center,Wuxi,Jiangsu 214000,China;Liver Disease Center,Department of Infectious Diseases,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang 325000,China)

机构地区：[1]江南大学附属中心医院肾内科,江苏无锡214000 [2]温州医科大学附属第一医院感染内科肝病中心,浙江温州325000

出　　处：《临床肝胆病杂志》2024年第1期42-45,共4页Journal of Clinical Hepatology

摘　　要：2020年,国际专家小组提出用代谢相关脂肪性肝病(MAFLD)来取代非酒精性脂肪性肝病(NAFLD)。近年研究发现MAFLD人群发生慢性肾脏疾病(CKD)的风险更高,并且阐明了MAFLD是CKD的独立风险因素。然而到目前为止,尚未提出MAFLD相关CKD预防及治疗的相关指导意见。笔者基于Delphi调查研究法,牵头来自26个国家的50名权威专家组成多学科小组就MAFLD和CKD之间联系的一些开放性研究问题达成了共识,阐明了MAFLD与CKD发病风险之间重要的临床关联,提高了对MAFLD和CKD的流行病学、发病机制、管理及治疗的认识,旨在为这两种常见且相互关联的疾病的早期预防和管理建立框架。In 2020,an international expert panel proposed to replace nonalcoholic fatty liver disease with metabolic associated fatty liver disease(MAFLD).Recent studies have shown that there is a higher risk of chronic kidney disease(CKD)in the MAFLD population and that MAFLD is an independent risk factor for CKD.However,up to now,there are still no guidelines on the prevention and treatment of MAFLD-related CKD.Based on the Delphi method,the authors led a multidisciplinary team of 50 authoritative experts from 26 countries to reach a consensus on some open-ended research issues about the association between MAFLD and CKD,which can help to clarify the important clinical association between MAFLD and the risk of CKD and improve the understanding of the epidemiology,pathogenesis,management,and treatment of MAFLD and CKD,so as to establish a framework for the early prevention and management of these two common and interrelated diseases.

关 键 词：代谢相关性脂肪性肝病 非酒精性脂肪性肝病 肾疾病 共识 

分 类 号：R692[医药卫生—泌尿科学] R575[医药卫生—外科学]